Cargando…

Discordant diagnostic criteria for pneumonia in COPD trials: a review

Inhaled corticosteroids (ICS) have a class effect of increasing pneumonia risk in patients with COPD. However, pneumonia incidence varies widely across clinical trials of ICS use in COPD. This review clarifies methodological differences in defining and recording pneumonia events in these trials and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wise, Robert A., Bafadhel, Mona, Crim, Courtney, Criner, Gerard J., Day, Nicola C., Halpin, David M.G., Han, MeiLan K., Lange, Peter, Lipson, David A., Martinez, Fernando J., Maselli, Diego J., Midwinter, Dawn, Singh, Dave, Zysman, Maeva, Dransfield, Mark T., Russell, Richard E.K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2021
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9488621/ https://www.ncbi.nlm.nih.gov/pubmed/34789465 http://dx.doi.org/10.1183/16000617.0124-2021

Ejemplares similares

Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease
por: Lipson, David A., et al.
Publicado: (2020)

Effect of chronic mucus hypersecretion on treatment responses to inhaled therapies in patients with chronic obstructive pulmonary disease: Post hoc analysis of the IMPACT trial
por: Thompson, Philip J., et al.
Publicado: (2022)

Time‐Dependent Risk of Cardiovascular Events Following an Exacerbation in Patients With Chronic Obstructive Pulmonary Disease: Post Hoc Analysis From the IMPACT Trial
por: Dransfield, Mark T., et al.
Publicado: (2022)

Risk of Exacerbation and Pneumonia with Single-Inhaler Triple versus Dual Therapy in IMPACT
por: Dransfield, Mark T., et al.
Publicado: (2021)

The effect of exacerbation history on outcomes in the IMPACT trial
por: Halpin, David M.G., et al.
Publicado: (2020)

Prognostic value of clinically important deterioration in COPD: IMPACT trial analysis
por: Han, MeiLan K., et al.
Publicado: (2021)

The Effect of Inhaled Corticosteroid Withdrawal and Baseline Inhaled Treatment on Exacerbations in the IMPACT Study. A Randomized, Double-Blind, Multicenter Clinical Trial
por: Han, MeiLan K., et al.
Publicado: (2020)

Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial
por: Day, Nicola C., et al.
Publicado: (2020)

InforMing the PAthway of COPD Treatment (IMPACT) trial: fibrinogen levels predict risk of moderate or severe exacerbations
por: Singh, Dave, et al.
Publicado: (2021)

Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT Study
por: Tabberer, Maggie, et al.
Publicado: (2020)

Single-inhaler triple therapy in symptomatic COPD patients: FULFIL subgroup analyses
por: Halpin, David M.G., et al.
Publicado: (2018)

Triple Versus Dual Combination Therapy in Chronic Obstructive Pulmonary Disease in Asian Countries: Analysis of the IMPACT Trial
por: Halpin, David M. G., et al.
Publicado: (2020)

FEV(1) Minimum Important Difference versus Minimal Detectable Difference? In Search of the Unicorn
por: Crim, Courtney, et al.
Publicado: (2021)

A randomized trial of once-daily fluticasone furoate/vilanterol or vilanterol versus placebo to determine effects on arterial stiffness in COPD
por: Bhatt, Surya P, et al.
Publicado: (2017)

Cost-Effectiveness Of Once-Daily Single-Inhaler Triple Therapy In COPD: The IMPACT Trial
por: Ismaila, Afisi S, et al.
Publicado: (2019)

Measuring disease activity in COPD: is clinically important deterioration the answer?
por: Singh, Dave, et al.
Publicado: (2020)

Correction to: Measuring disease activity in COPD: is clinically important deterioration the answer?
por: Singh, Dave, et al.
Publicado: (2021)

Single-Inhaler Triple Therapy in Patients with Advanced COPD: Bayesian Modeling of the Healthcare Resource Utilization Data and Associated Costs from the IMPACT Trial
por: Gabrio, Andrea, et al.
Publicado: (2022)

Reply to López-Campos et al.: Triple-Therapy Trials for Chronic Obstructive Pulmonary Disease: Methodological Considerations in the Mortality Effect
por: Lipson, David A., et al.
Publicado: (2021)

Validation of the Summit Lab Score in Predicting Exacerbations of Chronic Obstructive Pulmonary Disease Among Individuals with High Arterial Stiffness
por: Horne, Benjamin D, et al.
Publicado: (2021)

One More Time: The Impact of Inhaled Corticosteroid Withdrawal on IMPACT
por: Han, MeiLan K., et al.
Publicado: (2020)

Reply to Wang and Lai: The Role of Eosinophils during the Withdrawal of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease
por: Han, MeiLan K., et al.
Publicado: (2021)

Reply to Suissa: Mortality in IMPACT: Confounded by Asthma?
por: Lipson, David A., et al.
Publicado: (2020)

Clinical effectiveness of once-daily fluticasone furoate/umeclidinium/vilanterol in usual practice: the COPD INTREPID study design
por: Worsley, Sally, et al.
Publicado: (2019)

Discordant severity criteria in patients with moderate aortic stenosis: prognostic implications
por: Pio, Stephan M, et al.
Publicado: (2021)

Discordance between old and new criteria for stratifying patients with COPD
por: de Araújo, António Manuel Silva Duarte, et al.
Publicado: (2019)

International Differences in the Frequency of Chronic Obstructive Pulmonary Disease Exacerbations Reported in Three Clinical Trials
por: Calverley, Peter M. A., et al.
Publicado: (2022)

Discordance between clinical and immunological ART eligibility criteria for children in Malawi
por: O’Hare, Bernadette, et al.
Publicado: (2014)

Women's COPD
por: Zysman, Maéva, et al.
Publicado: (2022)

DISCORDANCE IN GOALS OF CARE BETWEEN PATIENTS WITH ADVANCED CANCER AND THEIR CAREGIVERS: DOES AGE PLAY A ROLE?
por: Lipson, Amy R, et al.
Publicado: (2019)

Discordances in the application of different criteria for quantification of paediatric abdominal obesity: an analysis of two Swiss studies
por: Pinto, A M, et al.
Publicado: (2013)

Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease
por: Halpin, David M. G., et al.
Publicado: (2021)

Benefit/Risk Profile of Single-Inhaler Triple Therapy in COPD
por: Bourbeau, Jean, et al.
Publicado: (2021)

From GOLD 0 to Pre-COPD
por: Han, MeiLan K., et al.
Publicado: (2021)

Reply to Thomson, to Neder et al., and to Wouters
por: Han, MeiLan K., et al.
Publicado: (2021)

Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective
por: Halpin, David M.G., et al.
Publicado: (2020)

Diagnosing COPD
por: Halpin, David MG
Publicado: (2006)

ABCD of the phosphodiesterase family: interaction and differential activity in COPD
por: Halpin, David MG
Publicado: (2008)

Staging of lymphoma under chimeric antigen receptor T-cell therapy: reasons for discordance among imaging response criteria
por: Winkelmann, Michael, et al.
Publicado: (2023)

Discordance Between Cerebrospinal Fluid Biomarkers and Amyloid Positron Emission Tomography in Alzheimer’s Sheds Light on Clinical Trial Exclusion Criteria
por: Major, Catherine K, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_86i83qqv0s5bqvmsqshmd3v9kj